Shear stress magnitude and transforming growth factor-βeta 1 regulate endothelial to mesenchymal transformation in a three-dimensional culture microfluidic device

RSC Advances ◽  
2016 ◽  
Vol 6 (88) ◽  
pp. 85457-85467 ◽  
Author(s):  
Sara G. Mina ◽  
Wei Wang ◽  
Qingfeng Cao ◽  
Peter Huang ◽  
Bruce T. Murray ◽  
...  
Keyword(s):  
Shear Stress ◽  
Growth Factor ◽  
Microfluidic Device ◽  
Transforming Growth Factor Beta ◽  
Transforming Growth Factor ◽  
Three Dimensional ◽  
Mesenchymal Transformation ◽  
Dimensional Cell ◽  
Tgf Β1

A novel microfluidic device with a three-dimensional cell culture chamber was developed to study the role of shear stress magnitude and transforming growth factor-beta 1 (TGF-β1) on endothelial to mesenchymal transformation (EndMT).

scholarly journals Optimizing Platelet-Rich Plasma (PRP) Injections: A Narrative Review

2020 ◽  
Vol 2 (1) ◽  
pp. e31-e47
Author(s):  
Chris Cherian ◽  
Gerard Malanga ◽  
Ken Mautner
Keyword(s):  
Growth Factor ◽  
Transforming Growth Factor Beta ◽  
Transforming Growth Factor ◽  
Platelet Rich Plasma ◽  
Vascular Endothelial ◽  
Potential Alternative ◽  
Activating Agent ◽  
Endothelial Growth Factor ◽  
Tgf Β1

Platelet-rich plasma (PRP) is an orthobiologic treatment that has gained popularity as a potential alternative treatment for various musculoskeletal conditions. The physiologic role of platelets in the healing cascade provides clarity regarding its potential as it releases various growth factors such as platelet-derived growth factor (PDGF), transforming growth factor beta-1 (TGF-β1), and vascular endothelial growth factor (VEGF). However, there are various characteristics of PRP treatments including platelet count, presence or absence of leukocytes and red blood cells, as well as the use of an activating agent that introduces heterogeneity among preparations. This aim of this article is to provide clarity, where available, regarding the optimal characteristics for PRP treatments regarding tendon and ligament injuries as well as articular and muscular pathology.

The role of transforming growth factor beta-1 (TGF-β1) in peritonitis-induced adhesions

1998 ◽  
Vol 114 ◽  
pp. A1390
Author(s):  
A.M. Ghellai ◽  
N. Chegini ◽  
O. Dou ◽  
J.M. Kaseta ◽  
J.W. Burns ◽  
...  
Keyword(s):  
Growth Factor ◽  
Transforming Growth Factor Beta ◽  
Transforming Growth Factor ◽  
Growth Factor Beta ◽  
Tgf Β1

Deciphering the Role of Transforming Growth Factor Beta (TGF-β1&2) during Tumor Promotion and Suppression in Primary Liver Cancer

2018 ◽  
Vol 56 (01) ◽  
pp. E2-E89
Author(s):  
S Pereira ◽  
L Rodrigues ◽  
D Častven ◽  
FL Mahn ◽  
S Dooley ◽  
...  
Keyword(s):  
Growth Factor ◽  
Liver Cancer ◽  
Transforming Growth Factor Beta ◽  
Transforming Growth Factor ◽  
Primary Liver Cancer ◽  
Tumor Promotion ◽  
Growth Factor Beta ◽  
Tgf Β1

AB0723 SERUM LEVELS OF TRANSFORMING GROWTH FACTOR BETA1 AND SCLEROSTIN AND THEIR CORRELATIONS WITH MRI AND LABORATORY FINDINGS IN PATIENTS WITH SPONDYLOARTHRITIS

2020 ◽  
Vol 79 (Suppl 1) ◽  
pp. 1656.1-1656
Author(s):  
I. Shynkaruk ◽  
O. Iaremenko ◽  
D. Fedkov ◽  
K. Iaremenko ◽  
K. Mazanko
Keyword(s):  
Ankylosing Spondylitis ◽  
Growth Factor ◽  
Disease Activity ◽  
Transforming Growth Factor Beta ◽  
Transforming Growth Factor ◽  
Activity Index ◽  
Serum Levels ◽  
Mri Changes ◽  
Tgf Β1

Background:There is an actual demand for searching the biomarkers which could reflect disease activity and MRI changes in sacroiliac joints (SIJ) and spine in patients with spondyloarthritis (SpA). Transforming growth factor-beta 1 (TGF-β1) is a cytokine that suppresses inflammatory cytokines but could augment inflammation [1]. A very recent study suggests a possible role of sclerostin (Scl) in the identification of SpA patients, but further studies are needed to prove its role as a disease activity and progression biomarker [2]. In general, the role of these biomarkers in SpA patients remains unknown due to controversial data about their levels in patients with SpA in comparison with healthy subjects and correlations with SpA activity.Objectives:This study was designed to determine TGF-β1 and Scl serum levels and its correlations with changes in spine and SIJ on MRI imaging, laboratory parameters and indices of disease activity and functional status in SpA patients.Methods:102 patients with SpA (mean age (M±σ) - 38.1±11.2, 67 males and 35 females) and 15 healthy age- and gender-matched controls were included in the study. C-reactive protein (CRP, mg/l) and erythrocyte sedimentation rate (ESR, mm/hr) were evaluated as inflammatory markers. Disease activity and functional impairment were moderate to high, mean Ankylosing Spondylitis Disease Activity Score (ASDAS-CRP) was 3.07±1.07, Bath Ankylosing Spondylitis Disease Activity Index (BASDAI, mm) - 45.3±18.6, Bath Ankylosing Spondylitis Functional Index (BASFI, mm) - 31.7±22.9.Serum levels of TGF-β1 (pmol/l) and Scl (pmol/l) were measured by ELISA. Spine MRI imagines were assessed for active inflammatory lesions using Berlin method (0-69, n=19). Active and chronic MRI changes in SIJ were scored by Spondyloarthritis Research Consortium of Canada (SPARCC) score (0-72) and Danish scoring method (0-48), respectively (n=67). Spearman correlation coefficient and Student t-test were used for statistical analysis.Results:Mean value of laboratory and MRI parameters were: CRP – 20.9±31.5, ESR – 27.1±22.1, Berlin score was 3.93±3.87, SPARCC – 22.5±11.9, Danish score – 20.5±9.83.Patients with SpA had significantly lower serum levels of biomarkers compared with the healthy controls: 285.3±186.9 vs 443.2±84.3, p=0.0017 - for TGF-β1, and 21.7±13.5 vs 31.2±10.5, p<0.0001 – for Scl.There were significant positive correlations for TGF-β1: strong - with active spine lesions by Berlin method (r=0.810, p<0.01), and weak - with CRP level (r=0.224, p=0.024). There were no correlations with MRI inflammatory changes in SIJ.Scl had weak negative correlation with SPARCC (r=-0.265, p=0.030), but not with Danish or Berlin scores.There were no other correlations, including ASDAS-CRP, BASDAI and BASFI for both TGF- β1 and Scl.Conclusion:Serum TGF- β1 and Scl levels are significantly lower in SpA patients comparing with non-SpA subjects. TGF- β1 positively correlates with disease activity (CRP and active MRI lesions in spine), but has no correlations with SIJ inflammation assessed by MRI. Scl negatively correlates with inflammatory MRI changes in SIJ, but not in the spine.References:[1]Vaez F. Rheum Res. 2017; 2(3): 103-107[2]Perrotta FM. J Immunol Res. 2018. doi: 10.1155/2018/9101964Disclosure of Interests:None declared

scholarly journals TRANSFORMING GROWTH FACTOR 1 AT LIVER TRANSPLANTATION

2015 ◽  
Vol 17 (3) ◽  
pp. 76-82 ◽  
Author(s):  
R. M. Kurabekova ◽  
O. P. Shevchenko ◽  
O. M. Tsiroulnikova
Keyword(s):  
Immune Response ◽  
Liver Transplantation ◽  
Growth Factor ◽  
Transforming Growth Factor Beta ◽  
Transforming Growth Factor ◽  
Transplant Patients ◽  
Tissue Changes ◽  
Tgf Β1 ◽  
Diagnostic And Prognostic Value

This review summarizes the current literature devoted to the analysis of the role of transforming growth factor beta 1 (TGF-β1) at liver transplantation. TGF-β1 plays a key role in the development of liver fi brosis, as well as in development of the immune response; its concentration in the blood and tissue changes in liver diseases. TGF-β1 levels in the blood of the recipients are associated with the development of liver fi brosis, the formation of immune tolerance and immune response to active infection. Measuring the level of TGF-β1 at liver transplantation may have diagnostic and prognostic value for assessing the graft condition. Currently, clinical data on the role of the cytokine at liver transplantation are not accumulated enough and further research on the relation of TGF-β1 levels with different clinical and laboratory parameters in liver transplant patients is needed. The review analyzed 54 sources of literature, more than half of which were published in the last fi ve years.

The role of neoadjuvant transforming growth factor beta inhibition to prevent local recurrences and distant metastasis in advanced thoracic malignancies

2009 ◽  
Vol 209 (3) ◽  
pp. S32
Author(s):  
Samuel S. Kim ◽  
Zvi G. Fridlender ◽  
Arminder S. Jassar ◽  
Aaron Blouin ◽  
Veena Kapoor ◽  
...  
Keyword(s):  
Growth Factor ◽  
Distant Metastasis ◽  
Transforming Growth Factor Beta ◽  
Transforming Growth Factor ◽  
Local Recurrences ◽  
Growth Factor Beta ◽  
Thoracic Malignancies
Sign in / Sign up

Export Citation Format

Share Document